Loading...

LGND LIGAND PHARMACEUTICALS INC Legal Disputes 8-K Filing

LGND

LGND

LIGAND PHARMACEUTICALS INC

(LGND)

2026 8-K

Merger Announcement

Financial Results Announced

Termination Notice

Merger Announcement

Financial Results Announced

Investor Update

Financial Results

Credit Agreement Update

Convertible Notes Offering

Financial Statements

Merger of Equals

Financial Statements

Merger Agreement

Financial Results

Financial Results

Financial Results Announcement

Departure of Directors or C...

Acquisition of APEIRON Biol...

Amendment to Credit Agreement

Acquisition of APEIRON Biol...

FDA Approval for Ohtuvayre

FDA Approval and Phase 3 Re...

Annual Meeting Results

Acquisition of Royalty Rights

Agreement for Royalty Right...

Bylaws Amendment

Financial Results Announcement

FDA Approval for ZELSUVMI

Expansion of Partnership

Amendment to Earnings Release

Financial Results Announcement

Acquisition of Royalty and ...

Credit Facility Agreement

Appointment of Director

Merger Agreement

Financial Results Announcement

Annual Meeting of Stockholders

Financial Results Announcement

External Links:

Ligand Pharmaceuticals announced the termination of its TR-Beta Program with Viking Therapeutics, effective May 4, 2026, due to Viking's alleged breach of agreement. Viking is contesting this termination, signaling potential disputes ahead.

AI Assistant

LIGAND PHARMACEUTICALS INC

2026

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.